Browse Articles

Discover research articles across all indexed journals

Glucagon-like peptide-1 receptor agonists and risk of pancreatic cancer in high-risk individuals: A multicenter real-world analysis.

Journal of Clinical Oncology Cho Han Chiang, Toru Yoshino, Junmin Song et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.126

126 Background: Individuals with benign pancreatic neoplasms, such as intraductal papillary mucinous neoplasms, and those with hereditary cancer susceptibility carry a substantially increased risk of pancreatic cancer. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have protective effects against pancreatic carcinogenesis. We therefore evaluated the association between GLP-1RA use and pancreatic cancer risk among high-risk individuals using a large real-world database. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, comprising de-identified electronic health records from over 140 healthcare organizations worldwide. Adults (≥18 years) with diabetes mellitus and high-risk pancreatic conditions, defined as benign pancreatic neoplasms or documented hereditary cancer susceptibility, were identified. Patients receiving GLP-1RAs were compared with non-users receiving alternative non–GLP-1RA diabetes therapies. Propensity score matching (1:1) was performed based on demographics, metabolic comorbidities, pancreatic risk factors, and baseline medications. The primary outcome was incident pancreatic cancer. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. Results: After 1:1 propensity score matching, GLP-1RA users and non-users were well balanced across baseline characteristics in both the benign pancreatic neoplasm and hereditary cancer susceptibility cohorts. Over a mean follow-up of approximately 2 years, GLP-1RA use was associated with a significantly lower risk of incident pancreatic cancer. Among individuals with benign pancreatic neoplasms, pancreatic cancer occurred in 21 of 456 GLP-1RA users compared with 42 of 456 non-users (HR, 0.54; 95% CI, 0.32–0.91; log-rank P = 0.019). Similarly, among patients with hereditary cancer susceptibility, pancreatic cancer occurred in 11 of 958 GLP-1RA users versus 26 of 958 non-users (HR, 0.46; 95% CI, 0.23–0.93; log-rank P = 0.027). Conclusions: In this large real-world analysis of high-risk individuals with diabetes mellitus, GLP-1RA use was associated with a significantly lower risk of pancreatic cancer. These findings suggest a potential protective association in populations at increased baseline risk. Prospective studies are warranted to confirm these observations and to elucidate underlying biological mechanisms.

A GAN-based multimodal framework for preoperative response prediction in HER2-negative locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy.

Journal of Clinical Oncology Jia Wei, Jing Zhang, Guoliang Zheng et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.111

111 Background: Gastric cancer is a leading global cause of cancer-related death, with approximately 77% of patients in China diagnosed at a locally advanced stage (LAGC). While neoadjuvant chemoimmunotherapy is standard, responses vary. Currently, the gold standard for evaluating treatment efficacy is postoperative pathological tumor regression grade (TRG), which cannot guide preoperative decision-making. Most existing models rely on single-modal data, such as CT imaging or pathological features, and are often limited by incomplete characterization of the tumor microenvironment or sampling bias. This study proposes a novel framework called Victory: an Incomplete Multi-modal Efficacy Prediction Model based on Generative Adversarial Networks. It imputes missing data and fuses CT and pathology features to predict treatment response preoperatively, aiming for personalized LAGC management. Methods: We analyzed 758 HER2-negative LAGC patients (2020-2025) from 3 Chinese centers. Cohorts were defined by data completeness. The Victory model was developed using a generative adversarial network to impute missing modalities, generating five types of input features. This enabled multi-modal feature fusion and prediction across various clinical scenarios.A clinical model incorporating CEA, PD-L1, tumor size, and Ca125 was also built. Model performance was evaluated using six metrics and Kaplan-Meier survival analysis. Results: The Victory model performed best with paired multimodal data. In the external validation cohort, the model trained on real paired multimodal data (rCT_rP) achieved an AUC of 0.9322, significantly outperforming models trained on single-modal data (single CT model rCT AUC = 0.6567; single pathology model rP AUC = 0.7847). Furthermore, integrating clinical data did not improve model performance. Conclusions: The Victory model establishes a novel generative artificial intelligence-based paradigm for multi-modal diagnosis and treatment. It provides an end-to-end framework—from data imputation and modality fusion to efficacy prediction—for CT imaging and pathological features. This tool offers feasible decision support for preoperative efficacy prediction and prognostic stratification in LAGC patients undergoing neoadjuvant chemoimmunotherapy, facilitating optimized individualized treatment planning.

Author Correction: Charge transfer in triphenylamine–tetrazine covalent organic frameworks for solar-driven hydrogen peroxide production

Nature Communications Amin Zadehnazari, Florian Auras, Dimitrios Koumoulis et al. Jul 01, 2026 DOI: 10.1038/s41467-026-75081-x

Chemical Engineering of Altermagnetism in Two-Dimensional Metal–Organic Frameworks

Journal of the American Chemical Society Diego López-Alcalá, Alberto M. Ruiz, Andrei Shumilin et al. Jul 01, 2026 DOI: 10.1021/jacs.5c22589

Social vulnerability and spatial patterns of COVID-19 mortality: Global implications for respiratory health equity

PLoS ONE Gregory D. Kearney, Ogugua Ndili Obi, Veeranna Maddipati et al. Jul 01, 2026 DOI: 10.1371/journal.pone.0352270

Background The pandemic highlighted geographic inequities in COVID-19 mortality worldwide, reflecting structural and social vulnerabilities that exacerbated respiratory disease outcomes. The primary aim of this study was to examine the spatial relationship between COVID-19 mortality and communities characterized by greater social disadvantage in North Carolina. This application highlights the value of spatial analytic approaches when considering inequities in respiratory mortality. Methods This study analyzed 25,051 COVID-19 deaths occurring in North Carolina from March 2020 through April 2022 using state vital statistics data and the Centers for Disease Control and Prevention, Social Vulnerability Index data. SaTScan™ was used to identify mortality hot spots, and Moran’s I in ArcGIS Pro was used to assess spatial autocorrelation at the ZIP-Code Tabulation Area level. The Mann–Whitney U test was used to assess differences in social vulnerability index scores in mortality hot spots areas and non-hot spots areas. Results Local bivariate analysis identified moderate spatial clustering characterized by high–high (mortality–vulnerability) hot spots and spatial outliers. In non-parametric testing, COVID-19 mortality hot spot areas had significantly higher, but modestly elevated, median overall social vulnerability index scores compared with non–hot spot areas (0.58 vs. 0.45; p  < 0.001). Conclusions Social vulnerability partially explains the observed spatial heterogeneity in COVID-19 mortality (2020–2022), with statistically significant spatial clustering consistently concentrated in areas of higher social vulnerability. This study highlights how pre-existing inequities in healthcare access and social conditions intensified mortality disparities during the pandemic.

Unraveling the Design Principles of Crystallographic Orientation for Ultralong, 8500 Cycled Fe‐Ion Battery

Advanced Materials Chao Cheng, Yalan Gu, Ye Hong et al. Jul 01, 2026 DOI: 10.1002/adma.73744

ABSTRACT Rechargeable aqueous Fe‐ion batteries using Fe anodes is very promising in stationary grid‐scale energy storage but suffer from hydrogen evolution (HER) and Fe corrosion. Herein, we present new insights on the design principle of crystallographic orientation of the metallic Fe anode for long lifespan, sustainable Fe‐ion batteries. Guided by a density functional theory simulation on optimal surface energy and adsorption energy, we obtained highly [110] oriented Fe by annealing the commercial Fe foil at 1000°C in Ar/H 2 atmosphere. The [110] oriented Fe foil with the maximum exposure of (110) plane shows the significantly decreased lattice defect, residual stress, and grain boundary density. Consequently, side reactions including HER and by‐product formation were well suppressed with enhanced Fe‐ion diffusion and charge transfer kinetics. Significantly, 8540 cycle‐lifespan at 5.0 A g −1 with 99.3% capacity retention was achieved in the full battery, which is not only very prominent in aqueous Fe 2+ ion battery systems, but also surpasses most of aqueous Zn 2+ , Mg 2+ ion batteries recently reported. Our findings demonstrate that uniform epitaxial Fe 2+ electrodeposition along the surface of preferred oriented Fe anode is an effective strategy to address the troublesome HER and corrosion issues in the aqueous battery using low‐cost, industrial Fe element.

Quantitative FRET FLIM imaging reveals multiple interactions between proteins of the ESYT, ORP, and VAP families at the endoplasmic reticulum membrane

Journal of Biological Chemistry Dounia Zamiati, Mouna Abdesselem, Oliver Nüsse et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113144

Autoimmune cytopenias associated with immune checkpoint inhibitors: A disproportionality analysis of FAERS.

Journal of Clinical Oncology Ratnadeep Biswas, Digvijay Singh Rajawat, Abhay Kapoor et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.83

83 Background: Immune checkpoint inhibitors (ICIs) enhance antitumor immunity but may disrupt peripheral tolerance, leading to immune-related adverse events. While dermatologic, endocrine, and gastrointestinal toxicities are well described, immune-mediated hematologic complications remain incompletely characterized. We evaluated the association between ICIs and autoimmune cytopenias using a large-scale pharmacovigilance database. Methods: We conducted a retrospective disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) from 2011 through 2025. ICIs were grouped as CTLA-4, PD-1, and PD-L1 inhibitors. Autoimmune cytopenias were defined using MedDRA preferred terms including autoimmune hemolytic anemia, immune thrombocytopenia, autoimmune neutropenia, and immune-mediated pancytopenia. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated comparing ICIs with all other drugs in FAERS. Internal class comparisons were performed. Serious outcomes, including death, were evaluated. Results: Among 268,135 ICI reports, 794 autoimmune cytopenia cases were identified (0.30%), compared with 11,254 cases among 32,473,224 non-ICI reports. ICIs demonstrated significant disproportionate reporting of autoimmune cytopenias (ROR 8.6, 95% CI 8.0–9.2). Signals were observed across all classes: CTLA-4 (99/34,519; 0.29%), PD-1 (607/177,425; 0.34%), and PD-L1 inhibitors (170/56,191; 0.30%), without marked differences between subclasses. Death was reported in 15.2% of CTLA-4, 16.1% of PD-1, and 17.6% of PD-L1 cytopenia cases. Conclusions: Immune checkpoint inhibitors are associated with strong disproportionate reporting of autoimmune cytopenias in FAERS, with consistent signals across drug classes and notable fatality proportions. Although causality cannot be established from spontaneous reporting data, these findings highlight rare but potentially life-threatening hematologic immune toxicities that warrant heightened clinical awareness and early diagnostic evaluation.

Comparative PK/PD and efficacy data of liposomal doxorubicin and EXODS (bio-engineered exosomes loaded with doxorubicin) in metastatic triple-negative breast cancer.

Journal of Clinical Oncology Abhishek Dutta, Swastika Paul, Sabyasachi Parida et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.57

57 Background: Adverse reactions like vomiting, fatigue, oral sores, severe tissue ulceration, and necrosis are common in patients after doxorubicin administration. Some adverse effects manifest and worsen over time, including cardiac toxicity. Similar side effects are also observed for liposomal doxorubicin. Doxorubicin hydrochloride (HCl) liposome injection can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was observed to be 11%. To tackle these toxic side effects, we have developed EXODS, which is a bio-engineered exosomal formulation of doxorubicin. Methods: To investigate the PK parameters of EXODS and Liposomal Doxorubicin 0.42mg/kg of the drugs was injected into BALB/C mice. The plasma and tissue concentration of doxorubicin was measured by HPLC. To understand the efficacy of EXODS as compared to Liposomal Doxorubicin, MDA-MB-231 cells were injected into NOD-SCID mice, and following tumor development 4.5mg/kg, 2.5mg/kg and 0.42mg/kg of EXODS and 4.5mg/kg Liposomal Doxorubicin were injected. The parameters observed were tumor volume reduction, signs of toxicity, and CA 15-3 biomarker. Results: Plasma concentration of Liposomal Doxorubicin was significantly higher with a C max of 1412.6 ng/ml, whereas only 2.5ng/ml of Doxorubicin was observed at 15mins time point following EXODS treatment. All other time-points were observed to be below the limit of quantification in the case of EXODS. Tissue distribution studies on Liposomal Doxorubicin showed considerable accumulation of Doxorubicin in the healthy organs like liver (42.26 ng/g), spleen (67.88 ng/g), pancreas (67.97 ng/g), and kidney (61.44 ng/g), whereas for EXODS, the presence of Doxorubicin was not observed in the liver, pancreas, or kidney. Although 42.45 ng/g of Doxorubicin was observed in the spleen. No other organs showed any accumulation of Doxorubicin in both the treatment groups. Tumor efficacy evaluation of EXODS and Liposomal Doxorubicin revealed that both treatment groups had a significant reduction in tumor volume as compared to the tumor control group. EXODS groups demonstrated better survival as compared to the standard Doxorubicin formulation. Further assessment revealed that EXODS significantly reduced CA-15-3 biomarker expression as compared to Liposomal Doxorubicin. Conclusions: Pooled data analysis revealed that EXODS displayed significant improvement in the survivability. EXODS demonstrated a remarkable safety profile and was also able to reduce the expression of CA-15-3, indicating a reduction in the chances of cancer metastasis as compared to standard Doxorubicin and Liposomal Doxorubicin.

Coexistence of percolative and quantum-confined charge orders in marginally twisted TiSe2/NbSe2 heterostructure

Nature Communications Lingke Xu, Yaozhenghang Ma, Run Wen et al. Jul 01, 2026 DOI: 10.1038/s41467-026-75050-4

Upcycling Commodity Polymers into Semiconductors by Sequential Grafting of Aromatic Units through Regioselective Iodination and Living Suzuki–Miyaura Catalyst-Transfer Polymerization

Journal of the American Chemical Society Jingjing Zhang, Jaeyong Ahn, Hyunwoo Park et al. Jul 01, 2026 DOI: 10.1021/jacs.6c08566

Lactiplantibacillus plantarum GUANKE alleviates Zearalenone-induced intestinal dysfunction by modulating oxidative stress and inflammation

PLoS ONE Qiaoning Chang, Yanchao Zhao, Han Li et al. Jul 01, 2026 DOI: 10.1371/journal.pone.0351300

Aims This study evaluated L. plantarum GUANKE’s protective effects on ZEN-induced intestinal dysfunction and explored its molecular mechanisms. Methods In vitro, IPEC-J2 cells were divided into control, ZEN (40 μM), GUANKE (20 MOI), and ZEN+GUANKE groups (24 h treatment). Cell viability (CCK-8), oxidative stress indicators (LDH, ROS, T-SOD, GSH, MDA), and inflammatory cytokine mRNAs ( IL-1β, IL-6, TNF-α, IL-10 ) were detected. In vivo, Balb/c mice were randomized into five groups (control, ZEN, GUANKE, ZEN + LG, ZEN + HG) for 28 days of intervention. Jejunum histology (H&E staining), oxidative stress/inflammatory factors (kits/ELISA), serum intestinal function indices (D-xylose, D-lactate, DAO), and transcriptomic analysis were performed. Results L. plantarum GUANKE significantly improved IPEC-J2 cell viability, reduced LDH release ( P  < 0.01) and ROS accumulation (P  < 0.001), restored T-SOD/GSH activities (P  < 0.05), decreased MDA ( P  < 0.05), suppressed pro-inflammatory cytokines (IL-1β, IL-6, TNF-α ; P  < 0.05), and upregulated IL-10 ( P  < 0.05). In mice , L. plantarum GUANKE increased villus height/crypt depth ratio ( P  < 0.01), restored antioxidant status ( P  < 0.05), and rebalanced cytokine expression ( P  < 0.05 for pro-inflammatory; P  < 0.01 for IL-10). Transcriptomic analysis suggested that ZEN activated the NF-κB pathway, while L. plantarum GUANKE treatment was associated with reduced pathway activity.

Ferroelectric Dynamic‐Field‐Driven Nucleation and Growth Model for Predictive Materials‐To‐Circuit Co‐Design

Advanced Materials Yi Liang, Soohyeon Kim, Tony Chiang et al. Jul 01, 2026 DOI: 10.1002/adma.73722

ABSTRACT Real ferroelectric devices operate under mixed and distorted time‐varying voltages, yet the standard nucleation‐growth frameworks used to interpret ferroelectric switching, most notably the Kolmogorov‐Avrami‐Ishibashi (KAI) and nucleation‐limited switching models (NLS), are derived under the critically limiting assumption of a constant electric field. Thus, the prevailing interpretation of ferroelectric switching dynamics fails under real operating conditions. Here we introduce a compact dynamic‐field‐driven nucleation and growth (DFNG) model that enables quantitative fits to switching transients across multiple ferroelectric materials to extract time‐varying domain wall velocity and growth dimensionality, even under arbitrary voltage waveforms. This capability then motivates its use in device modeling under complex signals spanning disparate time and frequency scales. Coupling the compact model to application‐related waveforms and a circuit‐level simulation platform facilitates a predictive materials‐circuit co‐design framework by linking nucleation and growth parameters to memory window, disturb error, speed, and energy dissipation for next‐generation ferroelectric technologies.

Cover

Journal of Biological Chemistry Jul 01, 2026 DOI: 10.1016/s0021-9258(26)02205-2

Comparative effectiveness of first-line ribociclib plus aromatase inhibitor versus palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer: A global real-world evidence study.

Journal of Clinical Oncology Shankar Biswas, Yashasvi Srivastava, Ayman Hamadttu Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.45

45 Background: CDK4/6 inhibitors combined with aromatase inhibitors (AIs) are the standard first-line therapy for HR+/HER2− metastatic breast cancer (mBC). While ribociclib demonstrated significant overall survival (OS) benefit in MONALEESA-2 (HR 0.76; p=0.008), palbociclib did not in PALOMA-2 (HR 0.96; p=0.34). No head-to-head randomized trial exists. Real-world comparative effectiveness data remain limited and inconsistent. Methods: Using the TriNetX Global Collaborative Network (171 healthcare organizations), we identified patients with HR+/HER2− mBC initiating first-line ribociclib+AI (Cohort A) or palbociclib+AI (Cohort B), with AI commenced within 30 days of CDK4/6i. 1:1 propensity score matching (PSM) balanced demographics, metastatic sites, modified Charlson comorbidities, and laboratory values. Outcomes included OS, real-world time to next treatment (rwTTNT), and safety. Cox proportional hazards, Kaplan-Meier, and risk analyses were performed. Results: Before matching, 742 ribociclib and 1,818 palbociclib patients were identified; after PSM, 702 per cohort were retained with well-balanced covariates (all standardized differences <0.10). Median follow-up was 393 days (ribociclib) vs 692 days (palbociclib). Key outcomes are shown in the Table. Ribociclib was associated with significantly lower mortality (median OS 2,165 vs 1,631 days). ILD risk was significantly lower with ribociclib (risk ratio 0.482; p=0.025), as was VTE (risk ratio 0.545; p=0.017). Arrhythmia showed a borderline higher rate with ribociclib, consistent with known QTc prolongation risk. Conclusions: In this large global real-world study, first-line ribociclib+AI was associated with statistically significant OS advantage over palbociclib+AI in HR+/HER2− mBC, with a comparable safety profile. These findings complement indirect comparisons from MONALEESA-2 and PALOMA-2 and support differential OS benefit between CDK4/6 inhibitors in real-world practice. Outcomes. Outcome Ribo+AI Events/N (%) Palbo+AI Events/N (%) HR (95% CI) p (log-rank) OS (deceased) 148/696 (21.3) 259/697 (37.2) 0.814 (0.664–0.999) 0.049 rwTTNT 178/647 (27.5) 229/622 (36.8) 0.981 (0.805–1.195) 0.848 Neutropenia 108/672 (16.1) 122/667 (18.3) 1.052 (0.810–1.366) 0.704 Arrhythmia 35/667 (5.2) 32/671 (4.8) 1.637 (1.001–2.677) 0.047 Hepatotoxicity 15/690 (2.2) 18/688 (2.6) 1.099 (0.548–2.204) 0.792 ILD/Pneumonitis 13/694 (1.9) 27/695 (3.9) 0.775 (0.395–1.521) 0.458 VTE 22/673 (3.3) 40/667 (6.0) 0.758 (0.447–1.285) 0.302 Nausea/vomiting 104/592 (17.6) 143/616 (23.2) 0.949 (0.734–1.226) 0.686 Fatigue 101/597 (16.9) 131/605 (21.7) 1.002 (0.771–1.303) 0.988

The intersection between frailty and unmet health-related social needs: Establishing the complex frailty paradigm.

Journal of Clinical Oncology Tammy Hshieh, Shannon Goniwiecha, Brionca D. Taylor et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.96

96 Background: Older adults diagnosed with cancer (OAC) experience unique challenges that are often complicated by frailty. However, the extent to which frailty and frailty-mediated outcomes intersect with unmet health-related social needs (HRSN) and limited to marginal health literacy remains unknown. Here, we introduce the complex frailty phenotype among OAC and its impact on treatment outcomes. Methods: Before scheduled consultation at the Dana-Farber Cancer Institute Gastrointestinal Cancer Center (DFCI GCC), OAC age 65 years and older undergo an electronic frailty assessment (EFA): a modified Rockwood frailty scale evaluating general health, functional independence, social support, medication use, nutrition, and mood. Summary domain scores range from: 0-0.19 (robust), 0.20-0.34 (pre-frail), and 0.35-1.00 (frail). Additional questionnaires include a New Patient Intake Questionnaire to capture self-perceived health, personal and family history, HRSN questionnaire, and BRIEF health literacy screening tool, available in 6 languages (English, Spanish, Arabic, Chinese, Russian, and Haitian Creole). All OAC receiving treatment at DFCI GCC are referred to the Older Adults with Gastrointestinal Cancer Program to address unmet HRSN and frailty through integrated geriatric and pharmacy co-management, tailored health education, care coordination, and referrals to assistance programs. To explore the prevalence of complex frailty in this cohort, we defined complex frailty as pre-frail or frail OAC with any reported unmet HRSN and limited to marginal health literacy. Results: From January 2022 through November 2025, 2,877 out of 3,804 OAC (75.6%) evaluated at DFCI GCC completed EFA (1,983 robust, 620 pre-frail, and 274 frail). Between April 2023 through November 2025, 27.1% of OAC reported any unmet need (43.1% financial needs, 37.5% housing needs, 29.4% transportation needs, 20.1% nutrition needs, 19.8% caregiving needs, 5.6% digital access needs, and 3.0% education needs (n=2,311). For OAC reporting unmet HRSN, 49.4% were pre-frail or frail vs. 23.0% among those with no reported HRSN (p>0.0001). Of those with unmet HRSN and limited/marginal health literacy, 60.2% were pre-frail or frail vs. 24.1% of those with either no reported unmet HRSN or health literacy scored adequate (p<0.0001). Conclusions: Frailty compounded by unmet HRSN and low health literacy may prognosticate worse outcomes for OAC with gastrointestinal cancers. Increased recognition of complex frailty and tailored interventions is necessary for this growing population. Our future work will examine the impact of interventions addressing both frailty and HRSN on survival outcomes for our OAC at DFCI and beyond. Clinical trial information: NCT04674267 .

Radical-omics reveals the hydrogen-abstraction pathway of isoprene oxidation

Nature Communications Huan Song, Hongyang Cui, Huabin Dong et al. Jul 01, 2026 DOI: 10.1038/s41467-026-74966-1

Interplay of Noncovalent Interactions in Phase Separation Mediated by Tyrosine-Rich and Arginine-Rich Polypeptides

Journal of the American Chemical Society Ruiwen Xu, Rui Wang, Cindy Qiu et al. Jul 01, 2026 DOI: 10.1021/jacs.6c06972

From catwalk to kitchen: A qualitative study of luxury fashion companies’ diversification into hospitality and restaurant sector

PLoS ONE Simone Luongo, Fabiana Sepe, Elena Lupolo et al. Jul 01, 2026 DOI: 10.1371/journal.pone.0350846

This study examines the strategic diversification of luxury fashion brands into the hospitality and restaurant industry, with a particular focus on sustainability. The objective is to explore the motivations behind this cross-industry expansion, the strategies employed and the sustainable practices integrated into such ventures. A qualitative research design is applied, drawing on semi-structured interviews with stakeholders from leading luxury fashion companies. This approach allows for an in-depth understanding of how experiential branding, strategic decision-making and sustainability are embedded within hospitality initiatives. The findings reveal that luxury brands enter the hospitality sector to enrich the brand experience, strengthen customer engagement and foster innovation in sustainability. Sustainable practices are identified both in operational management and in customer-facing activities, though the extent of integration varied across cases. The results underscore the dynamic relationship between experiential branding and sustainability, highlighting opportunities for competitive differentiation as well as challenges in aligning brand identity with new industry practices. This research contributes to the growing literature on luxury brand management and diversification by demonstrating how sustainability influences experiential strategies in cross-industry contexts. The originality of this paper lies in its integrated view of luxury branding, diversification and sustainability, showing how fashion companies leverage hospitality ventures to reinforce brand value and connect with socially conscious consumers.

Ebola at 50 — Lessons for Outbreak Response and Preparedness

New England Journal of Medicine Alimuddin Zumla, Francine Ntoumi, Nicaise Ndembi et al. Jul 01, 2026 DOI: 10.1056/nejmp2607819